Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    National Security
    Science & Regulatory
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Investor Forum
    BIO Asia-Taiwan

    July 15-19, 2026
    Taipei, Taiwan

    BIO Patient & Health Advocacy Summit
    BIO Patient Advocacy Changemakers Event

    October 22-23, 2026
    Washington, D.C

    BIO Asia-Taiwan
    BIO Europe

    November 9-11, 2026
    Cologne, Germany

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyNational SecurityScience & RegulatoryAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3199 results found
Expand All
Apply All
3199 results found

BIO International Convention Returns to San Diego to Celebrate Five Decades of Biotechnology
Share
Press Release  •  June 22, 2026
20,000+ biotech leaders gather with a shared mission: to improve lives  SAN DIEGO (June 22, 2026) - The BIO International Convention (BIO 2026), the world’s largest and most comprehensive event for the biotechnology industry, begins today in San Diego. The convention brings together 20,000+ biotech and life sciences leaders from around the world. This year’s theme, “Driven by Purpose,” reflects the industry’s commitment to solve the impossible, push boundaries, and deliver better outcomes for patients, public health, and the world. BIO 2026 features more than 150 sessions and 950+ speakers across 18 focus areas — from AI and digital health to diagnostics and personalized medicine, emerging opportunities in global markets, and more. Leading biotech executives, investors, service providers, government officials, regulators, and patient advocates representing the full ecosystem of biotechnology will connect over four days of networking, programming, and partnering. With nearly 10,000 partnering delegates and 70,000 partnering meetings expected to take place, BIO 2026 brings together leaders, investors, and innovators to advance innovation and business development across the industry.   “The BIO International Convention unites the world of biotechnology with great purpose,” said John F. Crowley, President & CEO of BIO. “As we celebrate 50 years of our biotechnology industry, this year’s convention brings together innovators, entrepreneurs, public health officials, and patient advocates prepared to tackle the hardest scientific challenges and to save and change lives for the next 50 years and more. This year’s theme ‘Driven by Purpose’ exemplifies what drives everyone in biotechnology – and will ensure we continue to drive the miracles of modern medicine needed to save and improve lives worldwide for the 21st century and beyond.”  Notable speakers and moderators at BIO 2026 include Gary Sinise, actor, humanitarian, and…
Read More

Product & Company Valuation
Share
BIO Professional Development Courses  •  June 21, 2026
The "Product & Company Valuation" course is designed to teach a systematic approach to producing a valuation that can be used in investment rounds, mergers/acquisitions, licensing deals, or strategic development decisions in the pharma-biotech world. This introductory course is very valuable for pharma and biotech executives who are not familiar with compound and company valuations but need a thorough understanding of the valuation concepts and techniques that are commonly applied in the pharma and biotech industries. It goes beyond the number-crunching techniques of most consultants and includes difficult to define qualitative factors, which shape the risk profile of the company in question. This course optimally balances interactive lectures with practical group work exercises that are designed to help you practice the fundamental valuation tools & techniques taught throughout the day.Valuation is an inherently subjective task, which is made even more difficult in the life science industry due to its unique challenges: high attrition rates in R&D, long investment cycle, complex technologies, IP situations, etc. Therefore, traditional valuation methods are not suitable. Of particular value in this course is the “Product Valuation and Deal Structuring” module where registrants will learn the commonly used rNPV (i.e., risk-adjusted Net Present Value) method for calculating the value of a drug in development. Subsequently, you will practice how to structure a licensing deal between companies. Registrants will use an Excel-based tool designed specifically for this module, which can be taken home for future use.Topics covered in the Product & Company Valuation course include:Introduction to valuationAssessing a company prior to valuationCompany valuation and methodsProduct valuation and methodsDeal structuringInterested in only registering for an in-person course in San Diego? If you do not plan to attend the Convention but would like to…
Read More

Advanced Business Development
Share
BIO Professional Development Courses  •  June 19, 2026
Advanced Business Development (ABD) is a long-running course focusing on all key aspects of transactions in the biopharma industry. This course is ideal for professionals ranging from those with limited experience (2–3 years) looking to advance their skills; and highly experienced dealmakers or executives looking to hone their skills and network with other dealmakers. Advanced Business Development incorporates lectures from experienced dealmakers, review of example models, dissection of actual deals, interaction with other participants, and live Q&A. Also, the course includes a mock negotiation scenario when each participant is a member of a deal team assigned to negotiate a transaction involving a drug in development with another team using an actual valuation and deal structuring model.Interested in only registering for an in-person course in San Diego? If you do not plan to attend the Convention but would like to register for a course only, please see the registration instructions and use the registration code provided below. This three-day course will be held in person, June 19--21, 2026, in San Diego, Calif. To add this course to your Convention registration, click the Register button.COURSE-ONLY REGISTRATION INSTRUCTIONSGo to our REGISTRATION WEBSITEStart New RegistrationEnter your Email, First Name, Last Name, and Company. Select “Continue”Provide requested personal information.Enter the code 26CRONLY in the first “Registration Code” box and select “Apply Code.”Select “Next”Complete the required fields. Review your information on the “Review and Check Out” page and select “Next” for payment options and to complete the registration.An e-mail confirmation will be sent automatically from the registration system. Please check your email filters if you do not receive them before contacting BIO.If you have any questions about the registration process, please contact the registration team at customercare@bio.org…
Read More

Business Development Fundamentals
Share
BIO Professional Development Courses  •  June 19, 2026
The Business Development Fundamentals in-person course provides a foundation of the key skills that are required to execute a licensing transaction. With a focus on the biopharma industry, the course is taught by senior executives who have personal experience and expertise in transactional and intellectual property law; business development – both sell and buy sides; finance; alliance management; negotiation, and university technology transfer.   Previous attendees include professionals from many international institutions. A sample of companies include: AlkermesNIHAmerican Society of HematologyGileadAmgenMerck National Taiwan UniversityBaylor College of MedicineNovartisBluebird BiosciencesQueensland University of TechnologyBiogenPfizerChinese University of Hong KongSanofiEli LillyTakedaEvotecUS Army Medical ResearchGenentech Who should take the course? Buy or sell-side business development or alliance management professionals with limited transactional experience Individuals interested in pursuing a career in business development, tech transfer, or alliance management Entrepreneurs Individuals who want to better understand the strategic role of business development in portfolio expansion or divestitures Interested in only registering for an in-person course in San Diego? If you do not plan to attend the Convention but would like to register for a course only, please see the registration instructions and use the registration code provided below. This three-day course will be held in person, June 19--21, 2026, in San Diego, Calif. To add this course to your Convention registration, click the Register button.COURSE-ONLY REGISTRATION INSTRUCTIONSGo to our REGISTRATION WEBSITEStart New RegistrationEnter your Email, First Name,…
Read More

PDUFA Frequently Asked Questions (FAQs)
Share
Human Health, Biotech Basics  •  Toolkit  •  June 19, 2026
What is PDUFA, why does it matter to patients, how often is it renewed, how is it reauthorized, and how does it affect drug development and approvals?
Read More

The History of PDUFA
Share
Human Health, Biotech Basics  •  Toolkit  •  June 19, 2026
Why was PDUFA enacted, how is it reauthorized, and how has PDUFA changed since it was first enacted? 
Read More

PDUFA At a Glance
Share
Human Health, Biotech Basics  •  Toolkit  •  June 19, 2026
What is PDUFA, why did Congress create it, and how does it advance innovation for patients?
Read More

BIO frequently provides webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services. Recordings of prior BIO
Share
BIO frequently provides webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services. Recordings of prior BIO webinars are searchable below.
Read More

Patient groups praise Virginia PDAB veto
Share
Bio.News  •  June 15, 2026
Patient groups happy Virginia won't have a PDAB. Plus, seeking clarity about onshoring agreements. (789 words, 3 minutes, 10 seconds)
Read More

Go From DNA to IND and Phase I Trials in Just 8 Months With Integrated AI/ML-Driven mAb Manufacturing
Share
Webinars  •  June 15, 2026
As monoclonal antibody (mAb) programs approach IND, delays often stem from fragmented development, tech transfer complexity, and limited process efficiency.In this webinar, Thermo Fisher Scientific presents a reengineered Path to IND for biologics platform that combines advanced platform science with integrated U.S.-based manufacturing to accelerate timelines and reduce risk.Join our Head of Technical and Scientific Affairs to explore:Expanded mAb manufacturing capacity: Future drug substance and product capacity in Plainville, MA to ease constraints and increase availability at sites like Groningen (NL) and Lengnau (CH).Advanced CHO-K1 platform with AI/ML: High-performing CHO-K1 cell line and process intensification achieving up to 11 g/L,* and enhanced by AI/ML-driven vector design and clone optimization to boost expression, stability, and speed.Accelerated path to IND: End-to-end biologics platform delivering IND-ready material in as little as 8 months with titer levels of up to 8 g/L.*Integrated process characterization and validation: Risk-based approach to PC, PV, and tech transfer to strengthen process robustness and help to accelerate PPQ readiness.Risk-mitigated development approach: Combines QbD, stage-gate governance, and qualified scale-down models to help to reduce variability and enable more predictable scale-up.Flexible scale model: Single-use bioreactor strategy (500–5,000 L) across a global network to streamline tech transfer from development through commercial manufacturing.Discover how integrating advanced cell line engineering, high-efficiency processes, and a unified U.S. manufacturing strategy can help bring your mAb therapy to IND faster—with greater control and confidence.
Read More
BTN-MTC_Researchers-DNA-364x210

Pagination

  • First First page
  • Prev Previous page
  • …
  • 4
  • 5
  • 6
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO Investment and Growth Summit
BIO Partnering™ for Oncology
BIO International Convention
BIO Partnering™ at JPM Week
BIO Patient Advocacy Changemakers Events
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO